Jefferies raises Inovio stock price target on regulatory win
Jefferies raised its price target for Inovio Pharmaceuticals (INO) to $8.00 from $3.00, maintaining a Buy rating. The stock, currently at $1.18, surged 141% over the past week. The upgrade follows FDA approval of VOCERYQ, Inovio's treatment for recurrent respiratory papillomatosis, positioning it as the second systemic entrant in the market. Inovio estimates 25,000 prevalent U.S. adult patients and plans to price the treatment at $460,000 per four-dose course.
How this was made
The 30-second read
Why it matters
The approval represents a material catalyst that could drive further price appreciation.
Market read
Regulatory win and analyst upgrades create a strong bullish case for INO.
What to watch
Reimbursement pathways and competition from other papillomatosis treatments.
Background
Inovio's stock surged 141% after the FDA approval and analyst upgrades.
Ticker impact
Inovio received FDA approval for its first product Voceryq, prompting analyst price target raises.
likely upward pressure as market prices in the approval and target upgrades
First FDA-approved DNA medicine, analyst upgrades and new price targets indicate strong catalyst.
Market effects
Boosts biotech sector sentiment on DNA‑based therapies.
U.S. biotech stocks may see broader gains.
Highlights FDA's role in advancing novel therapeutics worldwide.
Counterpoint
Potential pricing concerns at $460k per course could limit adoption.
Key entities
- companyInovio Pharmaceuticals
Biotech firm receiving FDA approval for Voceryq.
- analystJefferies
Raised price target to $8 on the approval.
- analystH.C. Wainwright
Upgraded to Buy with a $5 target.